SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-17-374199
Filing Date
2017-12-20
Accepted
2017-12-20 08:47:53
Documents
52
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q d495339d10q.htm 10-Q 651115
2 EX-31.1 d495339dex311.htm EX-31.1 8692
3 EX-31.2 d495339dex312.htm EX-31.2 8613
4 EX-32.1 d495339dex321.htm EX-32.1 4093
5 EX-32.2 d495339dex322.htm EX-32.2 4096
  Complete submission text file 0001193125-17-374199.txt   2623369

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT apls-20170930.xml EX-101.INS 296857
7 XBRL TAXONOMY EXTENSION SCHEMA apls-20170930.xsd EX-101.SCH 35053
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE apls-20170930_cal.xml EX-101.CAL 31927
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE apls-20170930_def.xml EX-101.DEF 140563
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20170930_lab.xml EX-101.LAB 268970
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20170930_pre.xml EX-101.PRE 211101
Mailing Address 6400 WESTWIND WAY SUITE A CRESTWOOD KY 40014
Business Address 6400 WESTWIND WAY SUITE A CRESTWOOD KY 40014 502-241-4114
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38276 | Film No.: 171265720
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences